Wockhardt Shares Soar 16% After US Clears Breakthrough Antibiotic for Drug-Resistant Infections

Mumbai, June 1:Wockhardtshare price surged as much as 16% on Monday after the company received approval from the US Food and Drug Administration (FDA) for its novel antibiotic ZAYNICH, a major regulatory milestone that strengthens its position in the global fight against antimicrobial resistance. The stock jumped as investors cheered the development and its commercial potential.

The FDA approved ZAYNICH, a combination of cefepime and zidebactam, for the treatment of adults suffering from complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative pathogens. The drug is designed to tackle multidrug-resistant bacterial infections, an area where treatment options remain limited globally.

As of writing, Wockhardt was up 8% at Rs 2,200.

Landmark Approval for Indian Pharma

Wockhardt got a big thumbs-up from the markets over the huge commercial potential of its breakthrough drug receiving US approval. Source: NSE

The approval marks a significant achievement for Wockhardt, coming just days after the antibiotic received regulatory clearance in India. The company said ZAYNICH had earlier been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA, reflecting the urgent need for new therapies targeting resistant bacterial infections.

According to Wockhardt, the drug works by targeting multiple penicillin-binding proteins simultaneously, enabling it to combat difficult-to-treat Gram-negative bacteria that have developed resistance to existing antibiotics. The company believes the therapy could address a growing global healthcare challenge as antimicrobial resistance continues to rise.

Strong Clinical Trial Results

Investor sentiment was also boosted by encouraging Phase 3 trial data that formed a key part of the FDA’s approval decision.

In the ENHANCE-1 study, ZAYNICH achieved a composite clinical cure and microbiological response rate of 89%, significantly higher than the 68.4% recorded by meropenem, one of the commonly used treatments for severe bacterial infections. The study enrolled 530 patients across multiple countries, including the United States, Europe, China and India.

The company said the treatment was generally well tolerated during the trial, further supporting its commercial prospects.

Multi-Billion Dollar Opportunity

Analysts view the approval as a potentially transformative event for Wockhardt, given the size of the global market for advanced antibiotics.

Industry estimates cited by reports suggest the addressable antibiotics market could be worth around $9 billion. Wockhardt is also expected to benefit from a period of market exclusivity, which could strengthen the commercial potential of the drug.

The company has already submitted a marketing authorisation application to the European Medicines Agency, with investors now closely watching further regulatory developments and commercial rollout plans.

The latest approval has reinforced optimism that Wockhardt’s years-long investment in antibiotic research could begin translating into meaningful revenue opportunities, helping reposition the company as one of the few Indian drugmakers with a globally approved innovative therapy targeting drug-resistant infections.

Source:

• https://www.nseindia.com/get-quote/equity/WOCKPHARMA/Wockhardt-Limited